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Background: The outcome is reported of a prospective uncontrolled study based on a stepwise treatment
protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong.
Method: One hundred and thirty eight patients were treated with broad spectrum antibiotics, a
combination of ribavirin and low dose corticosteroid, and then intravenous high dose methylprednisolone
according to responses. Sustained response to treatment was defined as (1) defervescence for >4
consecutive days, (2) resolution of lung consolidation by .25%, and (3) oxygen independence by the
fourth day without fever. Patients with defervescence who achieved either criterion 2 or 3 were classified
as partial responders. Patients who fell short of criteria 2 and 3 were non-responders.
Results: Laboratory confirmation of SARS coronavirus infection was established in 132 (95.7%). None
responded to antibiotics but 25 (18.1%) responded to ribavirin + low dose corticosteroid.
Methylprednisolone was used in 107 patients, of whom 95 (88.8%) responded favourably. Evidence of
haemolytic anaemia was observed in 49 (36%). A high level of C-reactive protein at presentation was the
only independent predictor for use of methylprednisolone (odds ratio 2.18 per 10 mg/dl increase, 95%
confidence interval 1.12 to 4.25, p = 0.02). Thirty seven patients (26.8%) required admission to the
intensive care unit and 21 (15.2%) required invasive mechanical ventilation. There were 15 deaths
(mortality rate 10.9%), most with significant co-morbidities, whereas 122 (88.4%) had been discharged
home 4 months after the outbreak onset.
Conclusion: The use of high dose pulse methylprednisolone during the clinical course of a SARS outbreak
was associated with clinical improvement, but randomised controlled trials are needed to ascertain its
efficacy in this condition.
I
n March 2003 there was a serious outbreak of severe acute
respiratory syndrome (SARS) in Hong Kong. One hundred
and thirty eight patients and healthcare workers contracted
the disease from a single index patient on a medical ward at
the Prince of Wales Hospital.1 Patients in this cohort had a
very similar presentation with fever, chills and rigor, myalgia,
and progression to respiratory failure within 1–2 weeks.
Within a month the disease had spread to Singapore,
Vietnam, Taiwan, Germany, Canada, and the United States.2
SARS is caused by a novel coronavirus (CoV),3–5 probably
originating from an animal reservoir. Without knowledge of
the underlying cause of the disease during the outbreak,
treatment of this newly emerging disease was empirical. A
team of physicians from the Department of Medicine and
Therapeutics (infectious disease, respiratory medicine and
general medicine) and the intensive care unit was formed to
manage the patients. A treatment protocol was developed in
response to the demands of the event. The results are
reported here.
METHODS
The data of our previously reported cohort1 recruited during
the 2 week period from 11 March to 25 March 2003 were
analysed. Because of the unexpected acute medical crisis with
many healthcare workers becoming infected, a blind control
study was not considered feasible. Instead, a stepwise
management algorithm was developed through observation
and discussion of the progress of the patients’ clinical
condition on a day-to-day basis. All data were prospectively
collected to assist future clinical management decisions. The
final clinical outcome is reported up to 28 July 2003.
Diagnosis and monitoring of progress
The CDC criteria for diagnosis of SARS were applied.6 Our
case definitions were: (1) fever (temperature .38 C˚), (2)
chest radiograph (plain radiograph and/or CT thorax)
showing evidence of consolidation with or without respira-
tory symptoms such as cough or shortness of breath, and (3)
history of exposure to an index case suspected of having
SARS or direct contact with a person who fell ill following
exposure to the index case.
Initial investigations included complete blood count
(including differential count), clotting profile (PT, APTT,
INR, D-dimer), C-reactive protein (CRP), and serum bio-
chemistry (including electrolytes, urea and creatinine levels,
serum alanine aminotransferase, creatine phosphokinase
(CPK), lactate dehydrogenase (LDH)). These parameters,
together with chest radiography and vital signs (blood
pressure, pulse, respiratory rate), were monitored regularly.
Serological examination for SARS CoV infection was
performed for all patients. The level of SARS CoV IgG
antibody was measured by an immunofluorescence assay
based on Vero cells infected with CoV isolated from a patient
with SARS. Paired serum samples were tested at serial
twofold dilutions starting from 1:40. The tests were regarded
as indicating SARS CoV infection if a seroconversion or
fourfold rise in antibody titre was detected. Viral isolation
using Vero cell culture has been previously described.1
Treatment protocol
Patients were treated for the first 2 days with broad spectrum
antibiotics for community acquired pneumonia according to
the American Thoracic Society guidelines.7 Initial treatment
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consisted of intravenous cefotaxime 1 g every 6 hours with
either oral levofloxacin 500 mg daily or clarithromycin
500 mg twice daily. Oseltamivir was also given to the initial
patients to treat possible influenza infection (fig 1). Clinical
symptoms, blood oxygen saturation, and the chest radio-
graph were assessed daily. If fever persisted after 48 hours,
patients were given a combination of ribavirin and ‘‘low
dose’’ corticosteroid therapy commencing on day 3–4 (oral
ribavirin as a loading dose of 2.4 g stat followed by 1.2 g
three times daily and prednisolone 0.5–1 mg/kg body weight
per day), whereas those with dyspnoea were treated with
intravenous ribavirin (400 mg every 8 hours) combined with
hydrocortisone (100 mg every 8 hours). Pulses of high dose
methylprednisolone (0.5 g intravenous infusion for three
consecutive days) were given as a response to persistence or
recurrence of fever and radiographic progression of lung
opacity with or without hypoxaemia despite initial combina-
tion therapy. Further pulses of methylprednisolone were
given if there was no clinical or radiological improvement, up
to a total of 3 g. The intention was to continue with the
combination of ribavirin and ‘‘low dose’’ corticosteroid for up
to 12 days when there was complete resolution of lung
opacity. Those who became afebrile but with incomplete
radiological resolution were given oral ribavirin 600 mg three
times daily and prednisolone 0.5 mg/kg body weight per day
for at least one further week.
Intensive care and mechanical ventilation
Patients who developed hypoxaemia were given supplemen-
tal oxygen. Patients were admitted to the intensive care unit
(ICU) when severe respiratory failure developed as evidenced
by (1) failure to maintain an arterial oxygen saturation of at
least 90% while receiving supplemental oxygen of 50% and/or
(2) respiratory rate .35 breaths/min. Non-invasive positive
pressure ventilation was avoided because of the risk of viral
transmission from mask leakage and flow compensation,
possibly causing wide dispersion of contaminated aerosol.
Criteria for intubation and positive pressure ventilation were
(1) persistent failure to achieve arterial oxygen saturation of
90% while receiving 100% oxygen via a non-rebreathing
mask and/or (2) onset of respiratory muscle fatigue as
evidenced by an increase in PaCO2, sweating, tachycardia,
and/or a subjective feeling of exhaustion. Mechanical
ventilation with synchronised intermittent mandatory venti-
lation or pressure control ventilation was instituted. Positive
end expiratory pressure and inspired oxygen concentration
were titrated to achieve an arterial saturation of 90–95%.
Tidal volume was maintained at 6–8 ml/kg estimated body
weight and plateau pressure maintained at 30 cm H2O or
less. PaCO2 was allowed to rise provided the pH was .7.15.
8
Patients unable to meet the above parameters were ventilated
in the prone position.
Definitions of clinical outcome
Sustained response (SR) to treatment was defined as (1)
defervescence (daily peak temperature (37.5 C˚) for at least
four consecutive days; (2) radiological improvement as
assessed by three radiologists who were blind to the clinical
data of more than 25%; and (3) oxygen independence as
assessed by pulse oximetry (SaO2 >95% on room air) on the
fourth afebrile day. Patients with defervescence who
achieved either resolution of lung consolidation or oxygen
independence, but not both, were classified as showing a
partial response (PR). Patients who fell short of criteria 2 and
3 above were classified as non-responders to treatment (NR).
Statistical analysis
Demographic, clinical, laboratory and radiological features of
the patients were reported and analysed. Statistical analysis
was performed by SAS software version 8.0 (SAS Inc, Cary,
NC, USA). Data are presented as mean (SD) unless otherwise
specified. The association between baseline parameters and
response to a combination of ribavirin and hydrocortisone
treatment was analysed by simple logistic regression.
Parameters measured during treatment were analysed using
either t test or Mann-Whitney test, depending on their
distribution. A stepwise multiple logistic regression analysis
was then performed to identify independent predictors for
failure to respond to ribavirin and low dose steroid, which
would lead to the subsequent use of pulse methylpredniso-
lone in accordance with our treatment protocol. All clinical
parameters with a p value of ,0.20 by univariate analysis
were entered into the model. A p value of ,0.05 was
considered statistically significant.
RESULTS
In the 2 week period from 11 March to 25 March 2003 a total
of 156 patients were admitted to the Prince of Wales Hospital
with SARS, of whom 138 were identified as either secondary
or tertiary cases stemming from our index patient. The
demography of this cohort has been described in detail in a
previous report.1 Briefly, there were 66 men and 72 women
with a mean (SD) age of 39.3 (16.8) years. The duration
between onset of symptoms and admission ranged from 0 to
11 days (median 3 days). Of these 138 cases, 124 subse-
quently showed seroconversion to SARS CoV while two had
negative SARS CoV serology. For the remaining 12, con-
valescent serum was not obtained but eight had SARS CoV
isolated from the nasopharyngeal aspirate (n = 3) or necro-
scopic lung and/or intestinal tissues (n = 5). Thus, only in
four patients was SARS CoV infection status not established.
None of the 138 cases responded to antibiotics. Fever
persisted in all and lung consolidation progressed in the
majority of patients. Ninety four patients received oral
ribavirin and prednisolone, of which 14 were sustained
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Oral ribavirin
Oral prednisolone
IV cefotaxime, oral levofloxacin
(or clarithromycin) and oseltamivir
Fever persisted after 48 hours,
lung shadow increased
Hypoxaemia
DyspnoeaNo dyspnoea
Fever persisted,lung
shadow increased
Hypoxaemia
IV methylprednisolone
for up to a max of 6 doses
Continue ribavirin and corticosteroid for a total of
12 days or until lung shadows totally subsided
Fever persisted,lung
shadow increased
Hypoxaemia
Hypoxaemia
Figure 1 Treatment protocol for SARS.
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responders and nine were partial responders. These 23
patients were discharged uneventfully. Two patients died in
the early phase of the disease before additional treatment
could be given. Forty four patients received intravenous
ribavirin and hydrocortisone, two of whom had a sustained
response and four died. The remaining 107 patients showed
no appreciable response to this combination treatment: 11
had persistent fever, 51 had radiological deterioration and
developed respiratory insufficiency, and 45 had both fever
and respiratory deterioration (fig 2). Overall, 25 patients
(18.1%) responded to ribavirin and low dose corticosteroid
treatment alone (table 1).
Intravenous pulse methylprednisolone was given to 107
patients who did not respond to ribavirin and low dose
corticosteroid therapy. After three infusions of 0.5 g per dose
of methylprednisolone, 45 patients (42.1%) showed a
sustained response with recovery from the disease and 52
(48.6%) had a partial response. Thirty one of those with a
partial response recovered and were discharged from
hospital, one died, and 20 required further pulses of high
dose methylprednisolone. There were 10 non-responders, one
of whom died. Among the partial responders and non-
responders, 29 received further doses of intravenous methyl-
prednisolone up to 3 g in total. A sustained response was
observed in five and a partial response in 13. Eleven patients
(median age 55 years, range 33–82) failed to show any
response after more than three pulses of high dose
methylprednisolone (fig 2). Of these, six died, one (who
has required invasive mechanical ventilation for 3 months)
remains in hospital for rehabilitation, and four were
discharged on a course of oral prednisolone at 0.5 mg/kg
after 3 weeks of hospitalisation. The overall success rate of
high dose methylprednisolone treatment was 88.8%.
As of 28 July 2003, there were 15 deaths (mortality rate
10.9%). The median age of these 15 patients was 69 years
(range 44–82). Two (aged 68 and 69 years) had an
unremarkable past history while 13 had at least one chronic
medical co-morbidity (including ischaemic heart disease,
rheumatic heart disease, congestive heart failure, myelodys-
plastic syndrome with malignant transformation, alcoholic
liver cirrhosis, reactivation of viral hepatitis B infection,
chronic renal impairment, and diabetes mellitus).
We have noted a typical clinical course of SARS. Fever
subsides after patients receive ribavirin and low dose
corticosteroid in the first week. While some patients remain
in remission, almost 80% of patients have recurrence of fever
with radiological progression by the second week. This is
accompanied by the development of respiratory symptoms
and hypoxaemia. Intravenous high dose methylprednisolone
usually controls the fever and results in resolution of lung
shadows and improvement in oxygenation. Biochemical
parameters and blood counts take 2–3 weeks to return to
normal (fig 3).
Hyperglycaemia (plasma spot glucose >11.0 mmol/l) was
detected in 23 of the 107 patients and hypokalaemia (plasma
potassium level (3.0 mmol/l) in 16. These metabolic
derangements were reversed when intravenous high dose
methylprednisolone was discontinued. Two patients devel-
oped transient confusion, delusion, and anxiety. CT scanning
and MR imaging of the brain revealed no abnormalities, and
the EEG and cerebrospinal fluid analysis were also normal.
The symptoms gradually subsided after discontinuation of
steroid.
The 25 patients who responded to ribavirin and low dose
steroid were compared with the 113 patients who did not
respond and needed further treatment with pulse methyl-
prednisolone (table 2). Initial platelet count, initial LDH,
systolic blood pressure, and initial CRP level reached
statistical significance by univariate analysis. Multivariate
analysis showed that a higher initial level of CRP (odds ratio
per 10 mg/dl, 2.18; 95% confidence interval 1.12 to 4.25;
p = 0.02) was the only independent risk factor for the use of
pulse methylprednisolone. Among the parameters recorded
during treatment, those who failed to improve after ribavirin
and low dose steroid had a significantly lower nadir
lymphocyte count and higher peak LDH and CRP levels.
Thirty seven patients (26.8%) were admitted to the ICU. Of
these, 21 (15.2%) required endotracheal intubation and
mechanical ventilation. Barotrauma was noted in eight
patients (21.6% of ICU admissions). Pneumomediastinum
with subcutaneous surgical emphysema was seen in three
cases and pneumothorax in five. In one case the pneu-
mothorax occurred within 24 hours of the insertion of a
central venous catheter in the internal jugular vein.
Nosocomial infection was diagnosed in 17 of the 37 patients
admitted to the ICU.9 10 In six the diagnosis of nosocomial
infection was made before high dose methylprednisolone
administration. Infections included pneumonia in 10 patients
(MRSA in six, Stenotrophomonas maltophilia in two, Candida
albicans in one, and polymicrobial in one), urinary tract
infections in two patients (Escherichia coli in one and
Enterococcus spp in one), and bacteraemia with no clearly
identified site in five patients (MRSA in three, Enterococcus
spp in one, and Candida albicans in one). Clostridium difficile
toxin was identified in one patient with diarrhoea. Sepsis
induced organ failure was considered to have contributed to
death in five cases.
SARS
(N = 138)
IV ribavirin and
hydrocortisone
(N = 44)
Oral ribavirin and
prednisolone
(N = 94)
Antibiotic therapy
(N = 138)
IV methylprednisolone
<3 doses
(N = 107)
IV methylprednisolone
>3 doses
(N = 29)
NR = 11 (6 died,
1 in hospital for
rehabilitation,
and 4 discharged)
Summary: 15 (10.9%) died,
122 (88.4%) discharged home, and
1 (0.7%) remained in hospital
SR: sustained response, PR: Partial response, NR: No response
SR = 0
SR = 2
NR = 4
SR all
discharged,
NR all died
SR = 14
PR = 9
NR = 2
SR and PR all
discharged,
NR all died
SR = 45 (all
discharged)
PR = 52
(1 died, 31
discharged)
PR = 13
(1 died, 12
discharged)
SR = 5 (all
discharged)
NR = 107
NR = 10, 1 died, 9 received
further methylprednisoloneN = 20
Figure 2 Clinical outcome of 138 patients with SARS (at 28 July 2003).
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After 2 weeks of treatment with ribavirin, 82 patients
(59%) had a fall in haemoglobin of more than 2 g/dl from
baseline while 39 (28%) experienced a fall of more than 3 g/dl.
Two weeks after initiation of ribavirin therapy haemoglobin
concentrations ranged from 7.2 to 13.2 g/dl. Evidence of
haemolytic anaemia was documented in 49 patients (36%)
with a rise of bilirubin (.20 mmol/l) and/or reticulocyte
count (.1%). No patients developed overt cardiac toxicity
or renal toxicity with ribavirin.
DISCUSSION
SARS is a serious infection with a formidable morbidity and
mortality. Of the 138 patients admitted to our hospital during
the major outbreak, 113 (81.9%) failed to improve after
ribavirin and low dose corticosteroid. High dose methylpred-
nisolone was used in 107 patients and 95 (88.8%) responded
favourably. Thirty seven patients (26.8%) required treatment
in the ICU, of whom 21 (15.2%) required invasive mechanical
ventilation. A high CRP level on admission was the only
independent predictor for use of high dose methylpredniso-
lone. As of 28 July 2003 (4 months from the outbreak onset),
122 patients (88.4%) had been discharged and one remained
in hospital for rehabilitation. The overall mortality was
10.9%, most with significant co-morbidities.
Similar to the description by Peiris et al,11 the clinical course
of our SARS patients appears to follow a typical pattern.
Phase 1 is clinically characterised by fever, myalgia, and other
systemic symptoms that generally improve after a few days.
Phase 2 is characterised by recurrence of fever, oxygen
desaturation, and radiological progression of pneumonia. The
clinical progression during phase 2 has also been observed by
others11 12 and appears to be related to immunopathological
damage.11 Most of our patients improved during this phase
with a combination of ribavirin and intravenous methyl-
prednisolone, but 15.2% progressed into acute respiratory
distress syndrome (ARDS) necessitating ventilatory support.
Reports from several other series have also suggested that a
substantial number of cases develop respiratory failure and
Table 1 Clinical response to treatment
Broad spectrum
antimicrobial* (n = 138)
Ribavirin + corticosteroid
(n = 138)
IV methylprednisolone`
(n = 107)
Sustained response 0 (0) 16 (11.6%) 50 (46.7%)
Partial response 0 (0) 9 (6.5%) 45 (42.1%)
No response 138 (100%) 113 (81.9%) 12 (11.2%)
*Antimicrobials included cefotaxime and clarithromycin (or levofloxacin) + oseltamivir.
Ribavirin (oral or intravenous) + oral prednisolone or intravenous hydrocortisone.
`Intravenous methylprednisolone up to 3 g in total.
Clinical outcome definitions: (1) afebrile (daily peak temperature (37.5 C˚) for at least 4 consecutive days; (2)
resolution of chest radiograph consolidation by .25% (comparing film of maximal consolidation and that on the
4th afebrile day); (3) oxygen independence (SaO2 >95% on room air) on the 4th afebrile day.
Sustained response = 1+2+3; partial response = 1+2 or 3; no response = failure to fulfil criteria of sustained
response and partial response.
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Figure 3 Clinical, biochemical, and haematological response of a patient to infusions of methylprednisolone.
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ARDS, with 17–30% of patients requiring admission to the
ICU,11–13 whereas the 21 day mortality was reported to be
3.6%1 and 6.5%,13 respectively. Necroscopic examination
revealed evidence of diffuse alveolar damage, pulmonary
oedema with hyaline membrane formation, and haemo-
phagocytosis in the lungs.1 14
To date there has been no consensus on the treatment of
SARS. Ribavirin, a broad spectrum antiviral agent previously
shown to be efficacious against both RNA and DNA viruses,
has been used.1 3 11–13 Previous studies have shown that, in
acute viral respiratory infections, large amounts of early
response cytokines such as interferon-a, tumour necrosis
factor a, interleukin (IL)-1 and IL-6 are produced. These
cytokines mediate antiviral activities but, at the same time,
may contribute to tissue injury.15 16 Ribavirin can inhibit viral
induced macrophage production of proinflammatory cyto-
kines and Th2 cytokines.17 Nevertheless, it has subsequently
been reported to have no significant in vitro activity against
the CoV believed to be responsible for SARS.18
High dose pulse corticosteroids have been used by several
groups with a favourable response.1 11 19–22 Corticosteroids
have been used because CT scans of the thorax have shown
radiographic features of bronchiolitis obliterans organising
pneumonia (BOOP)1 19 22 23 which is a steroid responsive
condition suggestive of an immunological phenomenon.24
The use of high dose pulse methylprednisolone treatment
aims to suppress the cytokine induced lung injury (phase
2).1 11 21 22 A retrospective study has shown that cases
receiving pulse methylprednisolone had a lower oxygen
requirement, better radiographic outcome, and were less
likely to require further rescue pulse steroid.22 In addition,
macrophages are the prominent leucocytes in the alveoli of
patients with fatal SARS, with evidence of haemophago-
cytosis in the lungs.14 Haemophagocytosis has been attributed
to cytokine dysregulation,25 and intervention with steroids
might modulate this cytokine response and prevent a fatal
outcome, as has been proposed for other causes of ARDS.14 26
Understandably, there are concerns about using high dose
methylprednisolone in an emerging infectious disease.
In this study the treatment protocol was developed during
a rapid major outbreak. The use of a relatively large dose of
oral ribavirin (loading dose 2.4 g followed by 3.6 g daily) was
based on the fact that the oral bioavailability of ribavirin is
only 36–52%.27 28 High dose methylprednisolone was used
only when ribavirin and low dose corticosteroid failed to stop
the inflammatory process, which was evident by continuing
radiological progression and hypoxaemia. Twenty five
patients (18%) responded favourably to ribavirin and low
dose corticosteroid treatment. Of these, 23 received oral
ribavirin and two received intravenous ribavirin; the numbers
were too small to allow a meaningful comparison between
them. With the dosage of ribavirin used we observed a
modest degree of anaemia in most patients (in 59% the
haemoglobin fell by 2 g/dl), probably the result of haemo-
lysis. A much higher dose of ribavirin, based on dosage for
treatment of haemorrhagic fever viruses,29 has been reported
to be associated with more significant toxicity including
haemolysis (in 76%) and a decrease in haemoglobin of 2 g/dl
(in 49%), raised transaminases (in 40%), and bradycardia (in
14% of SARS patients).13
Despite the combination of ribavirin and low dose
corticosteroid, most of the patients continued to deteriorate
during the second week of the illness. High dose methyl-
prednisolone was then used in 107 patients, 95 (88.8%) of
whom recovered from the progressive lung disease. Following
high dose methylprednisolone treatment, rapid resolution of
lung opacity was usually followed by an improvement in
hypoxaemia. Most patients responded after receiving three
doses of methylprednisolone (up to 1.5 g in total). Less than
30% of cases required additional doses. The timing of
Table 2 Univariate analyses of clinical and laboratory parameters associated with the use of intravenous pulse
methylprednisolone
Not responding to
ribavirin+low dose
steroid (n = 113)*
Responding to
ribavirin+low dose
steroid (n = 25)* Odds ratio (95% CI) p value
Parameters at presentation
Age (years) 39.9 (16.4) 37.5 (17.8) 1.01 (0.98 to 1.04) 0.5
Male sex (%) 48.7% 44.0% 1.21 (0.51 to 2.88) 0.7
Duration between onset of symptom and treatment (days) 5.4 (2.7) 6.1 (2.8) 0.91 (0.77 to 1.07) 0.2
Platelet (6109/l) 146 (58) 175 (64) 0.92 (0.86 to 0.99)` 0.03
Neutrophil count (6109/l) 4 (2) 3 (1) 1.30 (0.98 to 1.74) 0.1
Lymphocyte count (6109/l) 1 (1) 1 (1) 0.82 (0.45 to 1.48) 0.5
Activated partial thromboplastin time (s) 42.3 (7.3) 40.4 (10.4) 1.04 (0.97 to 1.11) 0.3
Sodium (mmol/l) 135.5 (3.5) 136.0 (2.5) 0.95 (0.83 to 1.09) 0.5
Urea (mmol/l) 4.8 (5.4) 4.4 (1.1) 1.02 (0.91 to 1.14) 0.7
Creatinine (mmol/l) 101 (118) 86 (22) 1.01 (0.98 to 1.03) 0.4
Alanine transferase (IU/l) 28.8 (30.1) 62.8 (158.1) 1.01 (0.99 to 1.03) 0.1
Creatinine kinase (U/l) 390.1 (675.1) 219.3 (272.3) 1.08 (0.95 to 1.23) 0.2
Lactate dehydrogenase (U/l) 370.4 (196.5) 262.4 (114.4) 1.56 (1.07 to 2.25) 0.02
Systolic blood pressure (mm Hg) 117 (18) 109 (11) 1.36 (1.02 to 1.83)` 0.04
Diastolic blood pressure (mm Hg) 62 (11) 61 (11) 1.07 (0.72 to 1.59)` 0.7
Pulse rate/min 94 (14) 92 (13) 1.15 (0.84 to 1.57)` 0.4
C-reactive protein (mg/dl) 51.9 (57.2) 9.6 (10.3) 2.18 (1.12 to 4.25)` 0.02
Parameters during treatment
Peak D-dimer (ng/ml) 1184 (1201) 1247 (2119) 0.3
Lymphocyte count (nadir) (6109/l) 0.3 (0.2) 0.6 (0.4) ,0.001
Creatinine kinase (peak) (U/l) 515.7 (761.4) 246.4 (268.8) 0.1
Lactate dehydrogenase (peak) (U/l) 468.6 (251.5) 279.0 (109.5) 0.001
Systolic blood pressure (nadir) (mm Hg) 95 (9) 94 (16) 0.6
Diastolic blood pressure (nadir) (mm Hg) 48 (7) 49 (8) 0.7
Pulse rate/min (peak) 107 (15) 99 (11) 0.01
C-reactive protein (peak) (mg/dl) 82.6 (83.8) 13.1 (15.7) ,0.001
*Values are mean (SD).
Per 100 units increase.
`Per 10 units increase.
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administration of high dose methylprednisolone is impor-
tant. It was administered only during phase 2 when
radiological progression of consolidation and increasing
hypoxaemia were documented.1 11 21 In most cases high dose
methylprednisolone was started towards the end of the first
week with the first pulse administered on day 8 (median)
from fever onset. We have avoided using high dose
methylprednisolone in the early phase of SARS11 as viral
clearance by host immunity might be hampered. It must be
emphasised that high dose methylprednisolone should not be
used only to control fever. In some patients the lung opacities
continued to deteriorate even after defervescence. In these
patients the benefit of high dose methylprednisolone in
reversing radiological progression was also seen. While we
recognise that the benefit of high dose methylpredniso-
lone1 11 19–22 cannot be confirmed without a control group, the
use of high dose corticosteroid in the treatment of SARS
warrants further investigation.
Our analysis indicated that patients with thrombocyto-
penia, high LDH, and high CRP levels at presentation were
more likely to have uncontrolled inflammation requiring
high dose corticosteroid therapy. Of these, a high CRP level at
presentation was the only independent factor of non-
response to ribavirin and low dose corticosteroid. During
treatment with ribavirin and low dose corticosteroid the non-
responders also had more severe lymphopenia, a higher peak
LDH, and a higher peak CRP level. While a high peak LDH is a
poor prognostic marker1 and is most likely the result of
immune mediated lung injury in severe cases of SARS,11
serial measurements of CRP may be useful in monitoring
response to treatment and detecting complications in
patients with secondary infections.30 31
In those patients admitted to the ICU the predominant
feature was isolated respiratory failure. All other recorded
organ failure was either pre-existing or could be attributed to
nosocomial infections. Despite low volume, low pressure
mechanical ventilation, the incidence of barotrauma (21.6%
of our ICU admissions) was surprisingly high. Chest radio-
graphs and CT scans did not indicate excessive hyperinflation
or bullous lung disease and, at present, we can offer no
explanation for this observation other than poor lung
compliance.23 Prone ventilation as salvage therapy appears
to have benefited some patients, but its use is controversial in
view of the lack of evidence supporting any benefit on
mortality.32 The unusually high rate of nosocomial infection,
particularly pneumonia, may have been the consequence of
corticosteroid treatment. More serious complications such as
disseminated fungal disease have been reported elsewhere.33
This report provides an account of a stepwise approach to
the treatment of SARS. The use of ribavirin has led to a
significant degree of haemolytic anaemia and the lack of in
vitro antiviral activity of ribavirin against SARS CoV18 has
rendered its role doubtful in the treatment of SARS. The use
of high dose methylprednisolone during clinical progression,
on the rationale of preventing immunopathological lung
injury,1 11 14 21 22 26 appeared to be effective in our cohort but
the limitation of interpreting uncontrolled data should be
noted. Randomised controlled studies will be required to
evaluate the efficacy and best timing for high dose
methylprednisolone treatment. It is hoped that the avail-
ability of the genome sequence of the SARS CoV34–36 will
facilitate efforts to develop new and rapid diagnostic tests,
antiviral agents, and vaccines in the long run.
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Chronic occupational exposure to nitrogen dioxide is associated with decline in lung
function
m Bakke B, Ulvestad B, Stewart P, Eduard W. Cumulative exposure to dust and gases as determinants of lung function
decline in tunnel construction workers. Occup Environ Med 2004;61:262–9
S
ix hundred and fifty one Norwegian male construction workers were followed for a
mean of 6 years with spirometric measurement and assessment of their occupational
exposure to total dust, respirable dust, a-quartz, volatile organic compounds, oil
vapour, oil mist, formaldehyde, nitrogen dioxide, and carbon monoxide. Compared with a
low exposure reference group of outdoor (non-tunnel) workers, tunnel workers showed a
decrease in lung function between the first and last spirometric assessments. The excess
annual decline in forced expiratory volume in 1 second (FEV1) in non-smoking tunnel
construction workers was 26 ml for drill and blast workers, 31 ml in tunnel concrete
workers, and 21 ml in shotcreters. The decrease in FEV1 was found to be significantly
associated with all exposures. Multiple linear regression modelling for decline in FEV1
showed that cumulative exposure to nitrogen dioxide had the strongest association of all the
agents.
This study demonstrates a decline in lung function in tunnel construction workers
exposed to nitrogen dioxide and other agents over a 6 year period. It highlights a need for
decreasing occupational exposure to nitrogen dioxide, and also to respirable dust and a-
quartz, which could be achieved by reducing diesel exhaust emissions and deployment of
respiratory devices to protect workers.
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